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Objective:  To  evaluate  the  impact  of  computerized  clinical  practice  guidelines  on  the  man-
agement,  diagnosis,  treatment,  control,  and  follow-up  of  the  main  cardiovascular  risk  factors:
hypertension,  hypercholesterolaemia,  and  type  2  diabetes  mellitus.
Design:  Pre-post  controlled  study.
Setting:  Catalonia,  autonomous  community  located  in  north-eastern  Spain.
Participants:  Individuals  aged  35--74  years  assigned  to  general  practitioners  of  the  Catalan
Health Institute.Hypercholesterolemia; Intervention:  The  intervention  group  consisted  of  individuals  whose  general  practitioners  had
 clinical  practice  guidelines  at  least  twice  a  day,  while  the  control
ls  whose  general  practitioner  had  never  accessed  the  computerized
platform.Type  2  diabetes
mellitus
accessed the  computerized
group consisted  of  individua
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Main  outcomes:  The  Chi-squared  test  was  used  to  detect  significant  differences  in  the
follow-up,  control,  and  treatment  variables  for  all  three  disorders  (hypertension,  hypercholes-
terolaemia,  and  type  2  diabetes  mellitus)  between  individuals  assigned  to  users  and  non-users
of the  computerized  clinical  practice  guidelines,  respectively.
Results:  A  total  of  189,067  patients  were  included  in  this  study,  with  a  mean  age  of  56  years
(standard  deviation  12),  and  55.5%  of  whom  were  women.  Significant  differences  were  observed
in hypertension  management,  treatment  and  control;  type  2  diabetes  mellitus  management,
treatment  and  diagnoses,  and  the  management  and  control  of  hypercholesterolaemia  in  both
sexes.
Conclusions:  Computerized  clinical  practice  guidelines  are  an  effective  tool  for  the  control
and follow-up  of  patients  diagnosed  with  hypertension,  type  2  diabetes  mellitus,  and  hyper-
cholesterolaemia.  The  usefulness  of  computerized  clinical  practice  guidelines  to  diagnose  and
adequately  treat  individuals  with  these  disorders  remains  unclear.
© 2016  Elsevier  España,  S.L.U.  This  is  an  open  access  article  under  the  CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Impacto  de  la  implementación  de  las  guías  de  práctica  clínica  electrónicas
en  el  diagnóstico,  control  y  tratamiento  de  los  factores  de  riesgo  cardiovascular:
un  estudio  pre-post  controlado
Resumen
Objetivo:  Evaluar  el  impacto  de  las  guías  de  práctica  clínica  electrónicas  en  el  manejo,  diag-
nóstico, tratamiento,  control  y  seguimiento  de  los  factores  de  riesgo  cardiovascular  mayores:
hipertensión,  hipercolesterolemia,  diabetes  mellitus  tipo  2.
Diseño: Estudio  pre-post  controlado.
Emplazamiento:  Cataluña,  comunidad  autónoma  situada  al  noreste  de  España.
Participantes:  Individuos  de  35-74  años  asignados  a  médicos  de  familia  del  Institut  Català  de
la Salut.
Intervención:  El  grupo  de  intervención  estaba  formado  por  pacientes  asignados  a  médicos  de
familia que  accedían  al  menos  2  veces  al  día  a  las  guías  de  práctica  clínica  electrónicas.  El
grupo de  control  estaba  formado  por  las  personas  asignadas  a  médicos  de  familia  que  nunca
habían accedido.
Medidas  de  resultado:  Se  realizaron  pruebas  de  ji  al  cuadrado  para  detectar  diferencias  sig-
nificativas  en  el  seguimiento,  control  y  tratamiento  de  la  hipertensión,  hipercolesterolemia  y
diabetes mellitus  tipo  2  entre  los  individuos  asignados  al  grupo  de  usuarios  y  los  no  usuarios  de
las guías.
Resultados:  Se  incluyeron  189.067  individuos,  con  una  edad  media  de  56  años  (desviación  están-
dar 12),  de  los  cuales  el  55,5%  eran  mujeres.  Se  encontraron  diferencias  estadísticamente
significativas  en  el  manejo,  tratamiento  y  control  de  la  hipertensión;  en  el  manejo,  tratamiento
y diagnóstico  de  la  diabetes  mellitus  tipo  2,  y  en  el  manejo  y  control  de  la  hipercolesterolemia
en ambos  sexos.
Conclusiones:  Las  guías  de  práctica  clínica  electrónicas  son  una  herramienta  efectiva  para  el
control y  seguimiento  de  los  pacientes  con  hipertensión,  hipercolesterolemia  y  diabetes  mellitus
tipo 2.  La  utilidad  de  las  guías  de  práctica  clínica  electrónicas  en  el  diagnóstico  y  adecuación
del tratamiento  sigue  en  discusión.



















he  socialization  of  evidence-based  medicine  as  the  sci-
ntific  basis  for  decision  making  in  the  field  of  health
echnology  has  promoted  the  availability  of  several  clinical
ractice  guidelines  (CPG).  These  tools  synthesize  informa-
ion  about  certain  pathologies  and  provide  action  patterns
ased  on  the  results  of  randomized  clinical  trials  or  on
he  consensus  of  prestigious  professionals.1 CPG  can  facil-
tate  decision-making  based  on  the  best  available  evidence






ndeed,  they  are  used  at  health  institutions  to  improve  the
uality  and  effectiveness  of  health  care.2,3
However,  in  recent  years  health  professionals  have
ot  systematically  applied  the  recommendations  provided
y  CPG,4 mainly  because  of  difficulties  in  accessing  the
ontent,  out-of-date  information,  lack  of  time  to  consult,
nfriendly  format,  insufficient  adaptation  to  the  health-
are  environment,  and  general  resistance  to  change  among
ealth  professionals.5--9
A  strategy  that  may  help  to  reduce  these  barriers  is  to













Implementation  of  electronic  clinical  practice  guidelines  for
records.5 This  is  the  approach  used  by  the  Catalan  Institute
of  Health.  Since  2004,  primary  care  centers  have  imple-
mented  electronic  health  records,  which  are  collected
and  managed  using  the  ECAP  software.  This  resource  has
recently  been  complemented  with  a  complex  system  that
integrates  an  electronic  version  of  CPG  (eCPG)  developed
by  the  Catalan  Institute  of  Health,  transforming  the  CPG
into  computerized  algorithms  in  order  to  facilitate  decision
making.
The  eCPG  for  hypercholesterolemia  (HCOL)  was  incorpo-
rated  to  ECAP  in  2010,  while  those  for  hypertension  (HTN)
and  type  2  diabetes  mellitus  (T2DM)  were  incorporated  in
2011.  These  eCPG  are  directly  activated  from  the  ECAP
and  use:  (1)  structured  information  about  the  patient  (age,
sex,  diagnoses,  and  active  prescription),  and  (2)  information
about  the  frequency  and  results  of  the  explorations.  Finally,
the  software  analyzes  the  control  and  creates  recommenda-
tions  about  the  most  adequate  treatment  and  management.
The  eCPG  also  incorporates  safety  issues  such  as  interactive
alerts  regarding  drugs  contra-indications  and  interactions.
The  eCPG  meets  key  requirements  proposed  by  several
authors  to  guarantee  its  successful  integration  into  elec-
tronic  medical  records  (easy  access,  reminders  to  guide
the  actions  of  health  care  professionals,  useful  feedback
to  inform  healthcare  professionals  about  the  appropriate-
ness  of  their  actions).  However,  the  real  effect  of  eCPG  on
the  clinical  results  of  the  attended  population  has  not  been
evaluated  in  detail.10--16
The  objective  of  the  present  study  was  to  evaluate  the
impact  of  integrating  eCPGs  for  the  management,  diagnosis,
treatment,  control  and  follow-up  of  three  key  cardiovascu-
lar  risk  factors  (HTN,  T2DM  and  HCOL).
Methods
Setting
This  study  was  performed  in  Catalonia  (Spain),  an
autonomous  community  with  7.5  million  inhabitants.  The
Catalan  Institute  of  Health  (ICS)  is  the  main  health  services
provider,  with  6  million  users,  and  a  network  of  329  primary
care  centers  with  5848  general  practitioners  (GP).
Study  design
We  conducted  a  before-after  controlled  study  to  ascertain
the  impact  of  eCPG  implementation.  The  study  protocol,
and  the  prevalence  and  control  of  cardiovascular  risk  factors
have  been  described  elsewhere.17,18
The  study  population  consisted  of  all  individuals  aged
35--74  years  who  were  assigned  to  the  ICS  GPs.  The  inter-
vention  group  consisted  of  individuals  whose  GPs  accessed
the  eCPG  environment  at  least  twice  a  day  between  June
2010  and  December  2012  (eCPG  users).  The  control  group
consisted  of  individuals  whose  GPs  had  never  entered  the
eCPG  environment  during  this  period.
The  study  protocol  was  approved  by  the  Ethics  Commit-
tee  of  the  Institut  d’Investigació  en  Atenció  Primària  Jordi
Gol  (authorization  #  P09/28).
Data  for  the  period  before  eCPG  implementation  were
collected  in  2008--2009  for  all  three  eCPGs.  To  study  thediovascular  risk  factors  391
ffect  of  the  eCPG  on  HCOL,  we  collected  data  between
une  2010  and  December  2012;  to  study  the  effect  of  eCPG
n  HTN  and  T2DM,  we  collected  data  between  October  2011
nd  December  2012.
ariables  measured
e  compared  the  numbers  of  individuals  who  met  the  next
riteria  before  and  after  the  intervention  (number  after
mplementation  minus  number  before):
 HTN:  (1)  New  diagnoses:  individuals  with  a  diagnosis
of  HTN.  (2)  New  treatments:  individuals  with  a  diagnosis  of
HTN  and  who  were  treated.  (3)  Improvement  in  control
of  HTN:  individuals  with  a  diagnosis  of  HTN  but  whose
blood  pressure  (BP)  was  under  control  (systolic  BP
<140  mmHg  and  diastolic  BP  <90  mmHg).  (4)  Improvement
in  control  of  HTN  in  secondary  prevention:  individuals  with
a  history  of  myocardial  infarction,  stroke  or  lower  extrem-
ity  peripheral  arteriopathy  with  a  diagnosis  of  HTN  but
whose  BP  was  under  control  (systolic  BP  <140  mmHg  and
diastolic  BP  <90  mmHg).  (5)  Individuals  with  a  diagnosis  of
HTN  who  had  had  a BP  determination  in  the  previous  12
months.
 T2DM:  (1)  New  diagnoses:  individuals  with  a  diagnosis  of
T2DM.  (2)  New  treatments:  individuals  with  a  diagnosis
of  T2DM  and  who  were  treated.  (3)  Improvement  in  con-
trol  of  T2DM:  individuals  with  a  diagnosis  of  T2DM  but
whose  glycated  hemoglobin  was  under  control  (<7.5%).
(4)  Improvement  in  control  of  BP  in  patients  with  T2DM:
individuals  with  T2DM  and  whose  BP  was  under  con-
trol  (systolic  BP  <140  mmHg  and  diastolic  BP  <90  mmHg).
(5)  Improvement  in  control  of  HCOL  in  individuals  with
T2DM  and  no  history  of  cardiovascular  disease:  individuals
with  a  diagnosis  of  T2DM  without  a  history  of  myocardial
infarction,  stroke  or  lower  extremity  peripheral  arteriopa-
thy,  and  whose  low  density  liporprotein  (LDL)  cholesterol
was  under  control  (<130  mg/dl).  (6)  Improvement  in  con-
trol  of  HCOL  in  individuals  with  T2DM  in  secondary
prevention  or  with  proteinuria:  individuals  with  a  diag-
nosis  of  T2DM  and  a  history  of  myocardial  infarction,
stroke,  lower  extremity  peripheral  arteriopathy  or  pro-
teinuria,  and  whose  LDL  cholesterol  was  under  control
(<100  mg/dl).  Finally,  among  individuals  with  a  diagnosis
of  T2DM,  we  compared  (pre-  vs.  post-implementation)  the
numbers  of  those  who  had  undergone  (7)  determination  of
glycated  hemoglobin,  (8)  electrocardiography,  or  (9)  the
eye  fundus  test  during  the  previous  12  months.
 HCOL:  (1)  New  diagnoses:  individuals  with  a  diagnosis  of
HCOL.  (2)  New  treatments:  individuals  with  a  diagnosis
of  HCOL  and  elevated  coronary  risk  who  were  treated.
(3)  Improvement  in  control  of  HCOL  in  primary  preven-
tion  (individuals  on  treatment):  number  of  individuals
without  a  history  of  myocardial  infarction,  stroke  or
lower  extremity  peripheral  arteriopathy  who  were  on
drug  treatment  and  whose  LDL  cholesterol  was  under
control  (<130  mg/dl).  (4)  Improvement  in  control  of
HCOL  in  secondary  prevention:  individuals  with  a  history
of  myocardial  infarction,  stroke  or  lower  extremity
peripheral  arteriopathy  whose  LDL  cholesterol  was  under
control  (<100  mg/dl).  (5)  Among  individuals  in  secondary
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compared  (pre-  vs.  post-implementation)  the  number
of  individuals  who  had  undergone  determination  of  LDL
cholesterol  in  the  previous  12  months.
We  also  considered  registry  variables  directly  associated
ith  the  use  of  eCPG  (e.g.  coronary  risk  registry,  T2DM
isk,  proteinuria  or  secondary  prevention  of  cardiovascular
isease).
Variables  were  collected  according  to  a  standardized
ethodology  described  elsewhere.17 The  information  source
as  the  ECAP  database.
tatistical  analysis
ontinuous  variables  are  presented  as  the  mean  and
tandard  deviation  (SD),  and  the  median  and  interquartile
ange  for  non-normally  distributed  variables.  Categorical
ariables  are  presented  as  proportions.  All  analyses  were
tratified  by  sex.
We  used  the  Chi-squared  test  to  detect  significant
ifferences  in  follow-up,  control  and  treatment  variables
or  all  three  disorders  (HTN,  T2DM  and  HCOL)  between
ndividuals  assigned  to  GPs  eCPG  users  and  non-eCPG  users.
ll  analyses  were  carried  out  using  the  R  Statistical  Package
R  Foundation  for  Statistical  Computing,  Vienna,  Austria;
ersion  3.2.0).
Patients  attended by 
non-users
n=120 861















Individuals 35-74  years 
n=920 461
Individuals  attended by  
users (at least two ent ries  a da y) or no n-user s (0  ent ries)
n=189 067
eneral  layout  of  the  studio:  Study  scheme:  Pre-post  controlled  study.  Participants  were  35-  to  74-year  olds  assigned
o  general  practitioners  of  the  Catalan  Health  Institute.  The  intervention  group  consisted  of  individuals  whose  general
ractitioners  had  accessed  the  electronic  clinical  practice  guidelines  at  least  twice  a  day,  while  the  control  group  consisted
f  individuals  whose  general  practitioners  had  never  entered  the  electronic  clinical  practice  guidelines  environment.
esults
89,067  individuals  were  included,  with  a  mean  age  of  56
ears  (SD:  12)  and  55.5%  women.  The  intervention  group
Participants’  baseline  characteristics  are  shown  in
Table  1.  The  profile  of  patients  assigned  to  each  group  was
similar  in  terms  of  sociodemographic  characteristics,  dis-
ease  prevalence,  and  control  of  cardiovascular  risk  factors.
Exceptionally,  there  was  a  higher  proportion  of  participants
with  high  cardiovascular  risk  in  the  non-eCPG  users  group
(4%  vs.  1.9%  in  women  and  14%  vs.  12.4%  in  men).  In  addition,
the  prevalence  of  smokers  was  slightly  lower  in  the  eCPG
users  group.  Control  of  HTN  and  T2DM  was  somewhat  higher
in  the  eCPG  users  group  in  both  sexes,  and  that  of  HCOL  was
higher  in  secondary  prevention  in  women.  The  character-
istics  of  this  cohort  following  intervention  are  provided  in
Supplementary  Table  1.
In  individuals  with  HTN  (Table  2  and  Fig.  1)  we  observed
significant  differences  in  all  variables  analyzed  in  favor
of  the  eCPG  users  group,  except  for  the  number  of  new
HTN  diagnoses  in  women.  The  greatest  differences  were
observed  in  the  control  of  HTN  in  individuals  in  secondary
prevention  (6.6  and  5.8  percentage  point  difference  in
women  and  in  men,  respectively).
In  T2DM,  we  observed  significant  differences  in  all  varia-
bles  analyzed  in  favor  of  the  group  of  eCPG  users  except
for  the  control  of  glycated  hemoglobin  in  women  (Table  3
and  Fig.  1). Regarding  outcome  variables,  the  greatest
differences  were  observed  in  the  control  of  hypercholes-
terolemia  in  individuals  with  T2DM  in  primary  prevention
(11.8  and  11.5  percentage  point  difference  in  women  and
men,  respectively).  In  addition,  we  observed  significant
differences  between  eCPG  users  and  non-users  in  the  perfor-
mance  of  follow-up  activities,  such  as  glycated  hemoglobinonsisted  of  individuals  who  were  attended  by  one  of  229
Ps  eCPG  users  (5.1%  of  all  ICS  GPs),  and  the  control  group
onsisted  of  individuals  who  were  attended  by  one  of  517




etermination,  the  electrocardiography  and  the  fundus.
We  did  not  observe  any  marked  differences  in  the  number
f  new  diagnoses  or  new  treatments  among  individuals  with
COL  (Table  4  and  Fig.  1).  In  contrast,  the  percentage  of
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Table  1  Characteristics  of  the  participants  in  the  cohort  prior  to  eCPG  implementation  (2008--2009)  according  to  whether  the
GP was  an  eCPG  user  or  non-user.
Women  Assigned  GP
Non-user
N  =  67,170
User
N  =  37,762
Age,  mean  (SD) 56  (12) 56  (12)
Smoker, n  (%)  4487  (18.0)  3230  (18.8)
Myocardial infarction  (registry),  n  (%) 1015  (1.5) 516  (1.4)
Stroke (registry),  n  (%)  649  (1.0)  362  (1.0)
Intermittent  claudication  (registry),  n  (%)  242  (0.4)  118  (0.3)
Hypertension  prevalence,  n  (%)  25,668  (38.2)  14,649  (38.8)
Hypertension  control  (<140/90  mmHg),  n  (%)a 15,440  (63.9)  8989  (65.4)
Type 2  diabetes  mellitus  prevalence,  n  (%) 6808  (10.1) 4241  (11.2)
Type 2  diabetes  mellitus  control  (Hba1c  <7.5),  n  (%)b 2490  (71.0)  2373  (73.4)
Hypercholesterolemia  prevalence,  n  (%)  24,769  (36.9)  14,185  (37.6)
Coronary risk  ≥10%,  n  (%)  604  (4.0)  267  (1.9)
Hypercholesterolemia  control  in  secondary  prevention  (LDL  cholesterol
<100 mg/dl),  n  (%)
255  (37.8)  244  (39.3)
Diagnosis or  treatment  for  hypertension,  type  2  diabetes  mellitus  or  hypercholesterolemia
1 risk  factor 20,772  (30.9)  11,250  (29.8)
2 risk  factors  12,964  (19.3)  7338  (19.4)
3 risk  factors  3515  (5.2)  2383  (6.3)
Men Non-user
N  =  53,691
User
N  =  30,444
Age,  mean  (SD)  56  (12)  56  (12)
Smoker, n  (%)  6709  (36.0)  4543  (33.7)
Myocardial infarction  (registry),  n  (%)  2973  (5.5)  1755  (5.8)
Stroke (registry),  n  (%)  990  (1.8)  558  (1.8)
Intermittent  claudication  (registry),  n  (%)  705  (1.3)  425  (1.4)
Hypertension  prevalence,  n  (%)  23,261  (43.3)  13,217  (43.4)
Hypertension  control  (<140/90  mmHg),  n  (%)a 12,870  (58.8%)  7547  (60.8%)
Type 2  diabetes  mellitus  prevalence,  n  (%) 8279  (15.4) 5121  (16.8)
Type 2  diabetes  mellitus  control  (Hba1c  <7.5),  n  (%)b 3170  (70.4%)  3164  (72.9%)
Hypercholesterolemia  prevalence,  n  (%)  22,256  (41.5)  13,161  (43.2)
Coronary risk  ≥10%,  n  (%)  1877  (14.6)  1486  (12.4)
Hypercholesterolemia  control  in  secondary  prevention  (LDL  cholesterol
<100 mg/dl),  n  (%)
909  (51.6%)  965  (52.1%)
Diagnosis or  treatment  for  hypertension,  type  2  diabetes  mellitus  or  hypercholesterolemia
1 risk  factor  18,023  (33.6)  9368  (30.8)
2 risk  factors  11,903  (22.2)  6966  (22.9)
3 risk  factors  3989  (7.4)  2733  (9.0)










a Individuals with diagnosis or treatment of hypertension.
b Individuals with diagnosis or treatment of type 2 diabetes mel
individuals  who  achieved  good  control  was  higher  in  patients
assigned  to  eCPG  users,  both  in  primary  prevention  (1.6
and  1.9  percentage  point  difference  in  women  and  men,
respectively),  and  particularly  in  secondary  prevention
(8.0  and  7.7  percentage  point  difference  in  women  and
men,  respectively).
We  did  not  observe  any  remarkable  differences  in  the
registry  of  coronary  risk,  diabetes  risk  and  proteinuria,
but  on  the  registry  of  cardiovascular  secondary  preven-
tion  (1.5  and  4.7  percentage  point  difference  in  women
and  in  men,  respectively),  where  we  observed  almost  the
same  prevalence  of  coronary  heart  disease  as  at  baseline






his  study  shows  that  patients  attended  by  eCPG  users
ad  better  control  and  follow-up  of  cardiovascular  risk
actors  than  those  attended  by  eCPG  non-users.  The  fre-
uent  use  of  eCPG  for  HTN  monitoring  has  substantially
mproved  BP  follow-up  and  control  in  all  patients,  partic-
larly  those  in  secondary  prevention.  The  eCPG  for  HCOL
lso  improved  control  of  cholesterol  levels,  which  were
lso  improved  in  secondary  prevention.  In  diabetic  patients,
e  did  not  observe  changes  in  control  after  1-year  of
ollow-up,  although  we  did  observe  an  improvement  in  the
umber  of  control  analyses,  electrocardiography  and  fundus
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Table  2  Pre-post  changes  in  patients  diagnosed  with  hypertension  according  to  whether  the  GP  was  an  eCPG  user  or  non-user.
Women  Assigned  GP
Non-user
N  =  25,668
User
N  =  14,649
p-Value
Pre  intervention--post  intervention
New  diagnoses  of  hypertension,  n  (%) 1233  (2.3)  771  (2.3)  0.972
New treatments  for  hypertension,  n  (%) 2401  (4.6) 2045  (6.1) <0.001
Improvements  in  the  control  of  patients  with  hypertension,  n  (%) 2451  (6.7) 2375  (9.8) <0.001
Improvements  in  the  control  of  patients  with  hypertension  in  secondary
prevention,  n  (%)
247  (12.2) 226  (18.8) <0.001
Activities of  post  intervention  follow-up
Blood  pressure  determination  21,371  (94.7)  12,515  (97.3)  <0.001
Men Non-user
N  =  23,261
User
N  =  13,217
p-Value
Pre  intervention--post  intervention
New  diagnoses  of  hypertension,  n  (%)  1290  (3.1)  881  (3.4)  0.010
New treatments  for  hypertension,  n  (%)  2361  (5.7)  2006  (7.7)  <0.001
Improvements  in  the  control  of  patients  with  hypertension,  n  (%)  2325  (7.9)  2305  (11.8)  <0.001
Improvements  in  the  control  of  patients  with  hypertension  in  secondary
prevention,  n  (%)
536  (12.0)  524  (17.8)  <0.001
Activities of  post  intervention  follow-up
















erformed.  Thus,  eCPG  is  useful  for  reminding  the  physician
f  and  promoting  relevant  actions  for  the  follow-up  of  these
ardiovascular  risk  factors.se  of  CPG
he  users  group  only  captured  5%  of  all  GPs  in  the  ICS,  indi-




igure  1  Changes  in  hypertension,  type  2  diabetes  mellitus  and  hyp
ollowing implementation  of  eCPG,  grouped  by  sex  and  according  to  w
2DM, type  2  diabetes  mellitus.ool.  These  low  rates  are  consistent  with  the  results  of  previ-
us  studies,5,7,9,13 and  may  be  due  to  various  factors:  health
rofessionals’  access  to  the  eCPG  decision  support  environ-
ent  is  voluntary;  health  professionals  often  resist  change;iseases  selected  for  this  study  (HTN,  T2DM  and  HCOL),  due
o  their  high  prevalence,7,8,13,19 such  that  most  GPs  did  not
eel  a  need  to  use  this  system  to  manage  these  diseases.
ercholesterolemia  control  in  primary  and  secondary  prevention
hether  the  GP  was  a  eCPG  user  or  non-user.  HTN,  hypertension;
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Table  3  Pre-post  changes  in  patients  diagnosed  with  type  2  diabetes  mellitus  according  to  whether  the  GP  was  an  eCPG  user
or non-user.
Women  Assigned  GP
Non-user
N  =  6808
User
N  =  4241
p-Value
Pre  intervention--post  intervention
New  diagnoses  of  type  2  diabetes  mellitus,  n  (%)  513  (1.0)  380  (1.2)  0.028
New treatments  for  type  2  diabetes  mellitus,  n  (%)  1151  (2.2)  876  (2.7)  <0.001
Improvements  in  the  control  of  Hba1c  in  patients  with  type  2  diabetes
mellitus,  n  (%)
228  (2.7) 221  (3.1)  0.133
Improvements  in  the  control  of  blood  pressure  in  patients  with  type  2
diabetes  mellitus,  n  (%)
1344  (19.4) 964  (22.5) <0.001
Improvements  in  the  control  of  hypercholesterolemia  in  patients  with
type 2  diabetes  mellitus  in  primary  prevention,  n  (%)
1513  (23.4)  1439  (35.2)  <0.001
Improvements  in  the  control  of  hypercholesterolemia  in  patients  with
type 2  diabetes  mellitus  in  secondary  prevention  or  proteinuria,  n  (%)
89  (10.4) 94  (14.9)  0.011
Post intervention  follow-up  activities
Hba1c  determination,  n  (%)  4692  (66.4)  4047  (91.0)  <0.001
Electrocardiography,  n  (%)  1970  (30.4)  2104  (51.9)  <0.001
Fundus, n  (%)  2225  (34.3)  1854  (45.7)  <0.001
Men Non-user
N  =  8279
User
N  =  5121
p-Value
Pre  intervention--post  intervention
New  diagnoses  of  type  2  diabetes  mellitus,  n  (%)  584  (1.4)  429  (1.7)  0.014
New treatments  for  type  2  diabetes  mellitus,  n  (%)  1294  (3.2)  1082  (4.2)  <0.001
Improvements  in  the  control  of  Hba1c  in  patients  with  type  2  diabetes
mellitus,  n  (%)
346  (4.0)  386  (4.8)  0.010
Improvements  in  the  control  of  blood  pressure  in  patients  with  type  2
diabetes  mellitus,  n  (%)
1683  (19.7)  1236  (22.3)  <0.001
Improvements  in  the  control  of  hypercholesterolemia  in  patients  with
type 2  diabetes  mellitus  in  primary  prevention,  n  (%)
1743  (21.5)  1758  (33.0)  <0.001
Improvements  in  the  control  of  hypercholesterolemia  in  patients  with
type 2  diabetes  mellitus  in  secondary  prevention  or  proteinuria,  n  (%)
353  (17.3)  401  (26.4)  <0.001
Post intervention  follow-up  activities
Hba1c  determination,  n  (%)  5841  (66.2)  5239  (90.8)  <0.001
Electrocardiography,  n  (%)  2551  (30.7)  2870  (52.7)  <0.001












Despite  the  low  rate  of  use,  eCPG  are  particularly  useful
for  the  management,  control  and  follow-up  of  multimorbid
patients.  It  seems  likely  that  the  integration  of  interac-
tive  alerts  regarding  poor  control  and/or  follow-up  on  a
screen  containing  details  of  all  of  the  patient’s  patholo-
gies  would  be  key  to  obtaining  the  best  results  in  patients
attended  by  eCPG  users.  Previously,  Niès  et  al.  concluded
that  automatic  alerts  were  more  effective  than  decision
support  systems,19 possibly  because  they  require  voluntary
activation  and  are  not  widely  known;  these  observations  are
consistent  with  our  results  regarding  treatment  and  diagno-
sis.  Certainly,  we  did  not  find  significant  differences  between
eCPG  users  and  nonusers.  Our  results  agree  with  other  stud-
ies  that  have  shown  that  eCPG  are  useful  for  improving
patient  follow-up  but  have  lower  short-term  impact  on  clin-
ical  variables.12,20--24 Our  study  complies  with  the  quality




ystem  should  be  integrated  into  medical  records,  should
btain  data  directly  from  these  medical  records,  should  be
ested  in  a  pilot  study,  and  eCPG  users  should  receive  train-
ng  on  how  to  use  the  system.  Indeed,  in  our  study  more  than
alf  of  the  variables  measured  showed  significant  improve-
ents  in  eCPG  users  than  in  nonusers.
mpact  of  eCPG
he  results  of  this  study  suggest  that  the  main  added  value
f  eCPG  is  the  use  of  a  pop-up  alert  system  to  highlight
oor  control,  lack  of  proper  follow-up,  and  a  comprehensive
pproach  to  multimorbid  patients.
Regarding  treatment,  the  limited  impact  of  eCPG  may  be
ue  to  the  already  broad  knowledge  that  GPs  have  about  the
athologies  and  risk  factors  studied.  Regarding  our  results,
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Table  4  Pre-post  changes  in  patients  diagnosed  with  hypercholesterolemia  according  to  whether  the  GP  was  an  eCPG  user  or
non-user.
Women  Assigned  GP
Non-user
N  =  24,769
User
N  =  14,185
p-Value
Pre  intervention--post  intervention
New  diagnoses  of  hypercholesterolemia,  n  (%)  5441  (10.1)  3356  (10.1)  0.946
New treatments  for  hypercholesterolemia  in  patients  with  coronary  risk
≥10%,  n  (%)
62  (0.1)  77  (0.2)  <0.001
Control of  hypercholesterolemia  in  primary  prevention  (treated
patients),  n  (%)
1512  (2.3) 1453  (4.0) <0.001
Control of  hypercholesterolemia  in  secondary  prevention,  n  (%)  106  (6.3)  126  (14.3)  <0.001
Post-intervention  follow-up  activities
LDL-cholesterol  determination  in  patients  in  secondary  prevention
or under  lipid-lowering  treatment
204  (15.9)  128  (16.3)  0.836
Men Non-user
N  =  22,256
User
N  =  13,161
p-Value
Pre  intervention--post  intervention
New  diagnoses  of  hypercholesterolemia,  n  (%)  4440  (10.3)  2627  (10.0)  0.321
New treatments  for  hypercholesterolemia  in  patients  with  coronary  risk
≥10%,  n  (%)
320  (0.8)  345  (1.4)  <0.001
Control of  hypercholesterolemia  in  primary  prevention  (treated
patients),  n  (%)
1292  (2.5)  1288  (4.4)  <0.001
Control of  hypercholesterolemia  in  secondary  prevention,  n  (%)  329  (8.5)  366  (16.2)  <0.001
Post-intervention  follow-up  activities
LDL-cholesterol  determination  in  patients  in  secondary  prevention
or under  lipid-lowering  treatment












































here  is  room  for  improvement  in  the  use  of  eCPGs  whenever
hese  tools  are  integrated  into  a  single  work  and  registry
nvironment,  with  automatic  pop-up  alerts  that  are  easily
dentifiable  and  limited  to  relevant  issues,  and  are  delivered
ia  easy-to-use,  intuitive  support  systems.  Key  elements  to
ncrease  the  use  of  these  tools  include  the  GP  scheme  used
o  incentivise  GPs,  pending  activities  reminders,  feed-back
n  GPs’  actions,  continuous  updating  of  contents,  and  GP
ngoing  training  for  GPs.3,10,14,25
eCPGs  facilitate  a  comprehensive  approach  to  patients.
ultimorbid  patients  in  secondary  prevention  achieve  bet-
er  control  and  follow-up,  which  likely  improves  long-term
utcomes.  However,  longer  follow-up  would  be  required  to
scertain  the  true  long-term  impact.
haracteristics  and  limitations
his  study  has  been  conducted  under  real  clinical  practice
onditions,  which  increases  its  external  validity,  although
aution  is  needed  before  generalizing  the  results.  Since  we
ave  focussed  on  eCPG  users  and  nonusers,  the  majority  of
rofessionals  have  not  been  included  in  this  study.  Nonethe-
ess,  the  large  sample  size  analyzed  and  the  strategy  used  for
articipant  selection  increases  the  study’s  representative-





Our  study  has  various  limitations.  First,  the  quasi-
xperimental  design  means  that  we  cannot  definitively
ttribute  the  observed  differences  to  the  implementation  of
CPGs.  The  GPs  that  decided  to  use  the  eCPGs  were  likely
ifferent  to  those  who  did  not  use  these  tools,  although
here  were  minimal  differences  between  the  two  cohorts
efore  implementation  of  the  eCPG.  Unfortunately,  we  did
ot  have  data  regarding  GPs  characteristics  of  each  group
e.g.  users  and  non-users).  Second,  the  ICS  has  developed
 progressive  incentive  scheme  for  professionals,  and  also
ffers  feedback  systems  to  improve  assistance  and  phar-
aceutical  quality.  These  recommendations,  which  include
he  pathologies  analyzed  in  this  study,  may  have  minimized
he  impact  of  the  eCPG.  Finally,  a  longer  follow-up  period
ould  be  required  to  evaluate  the  true  impact  on  health
utcomes.
We  conclude  that  eCPGs  are  an  effective  tool  for  control-
ing  and  conducting  follow-up  on  patients  diagnosed  with
TN,  T2DM  and  HCOL.  The  utility  of  eCPG  to  adequately
iagnose  and  treat  individuals  with  these  pathologies  is  still
nclear.unding support
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What is already known?
Clinical  practice  guidelines  can  facilitate  decision-
making  based  on  the  best  available  evidence  and  can
decrease  unjustified  variability  in  clinical  practice.
A  strategy  that  may  help  to  increase  the  applica-
tion  of  clinical  practice  guidelines  in  primary  care  is  to
integrate  these  tools  into  health  providers’  electronic
medical  records
What does this study adds?
Patients  attended  by  electronic  clinical  practice  guide-
lines  users  had  better  control  and  follow-up  of
cardiovascular  risk  factors  than  those  attended  by  eCPG
non-users.
Electronic  clinical  practice  guidelines  are  useful  for
reminding  the  physician  of  and  promoting  relevant
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